Cysteinyl leukotriene receptor 1 is dispensable for osteoclast differentiation and bone resorption

PLoS One. 2022 Nov 17;17(11):e0277307. doi: 10.1371/journal.pone.0277307. eCollection 2022.

Abstract

Cysteinyl leukotriene receptor 1 (CysLTR1) is a G protein-coupled receptor for the inflammatory lipid mediators cysteinyl leukotrienes, which are involved in smooth muscle constriction, vascular permeability, and macrophage chemokine release. The Cysltr1 gene encoding CysLTR1 is expressed in the macrophage lineage, including osteoclasts, and the CysLTR1 antagonist Montelukast has been shown to suppress the formation of osteoclasts. However, it currently remains unclear whether CysLTR1 is involved in osteoclast differentiation and bone loss. Therefore, to clarify the role of CysLTR1 in osteoclastogenesis and pathological bone loss, we herein generated CysLTR1 loss-of-function mutant mice by disrupting the cysltr1 gene using the CRISPR-Cas9 system. These mutant mice had a frameshift mutation resulting in a premature stop codon (Cysltr1 KO) or an in-frame mutation causing the deletion of the first extracellular loop (Cysltr1Δ105). Bone marrow macrophages (BMM) from these mutant mice lost the intracellular flux of calcium in response to leukotriene D4, indicating that these mutants completely lost the activity of CysLTR1 without triggering genetic compensation. However, disruption of the Cysltr1 gene did not suppress the formation of osteoclasts from BMM in vitro. We also demonstrated that the CysLTR1 antagonist Montelukast suppressed the formation of osteoclasts without functional CysLTR1. On the other hand, disruption of the Cysltr1 gene partially suppressed the formation of osteoclasts stimulated by leukotriene D4 and did not inhibit that by glutathione, functioning as a substrate in the synthesis of cysteinyl leukotrienes. Disruption of the Cysltr1 gene did not affect ovariectomy-induced osteoporosis or lipopolysaccharide-induced bone resorption. Collectively, these results suggest that the CysLT-CysLTR1 axis is dispensable for osteoclast differentiation in vitro and pathological bone loss, while the leukotriene D4-CysTR1 axis is sufficient to stimulate osteoclast formation. We concluded that the effects of glutathione and Montelukast on osteoclast formation were independent of CysLTR1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Resorption* / genetics
  • Bone Resorption* / pathology
  • Female
  • Glutathione / pharmacology
  • Leukotriene D4 / pharmacology
  • Leukotrienes
  • Mice
  • Osteoclasts*

Substances

  • leukotriene D4 receptor
  • montelukast
  • Leukotriene D4
  • cysteinyl-leukotriene
  • Leukotrienes
  • Glutathione

Grants and funding

This study was funded by Japan Society for the Promotion of Science (https://www.jsps.go.jp/english/index.html), (JSPS KAKENHI 15K10475, 19K09625, awarded to HF) and the Promotion of Science and Technology in Okayama Prefecture by the MEXT (https://www.mext.go.jp/) (awarded to HO). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.